Literature DB >> 21455928

Should possible recurrence of disease contraindicate liver transplantation in patients with end-stage alveolar echinococcosis? A 20-year follow-up study.

Solange Bresson-Hadni1, Oleg Blagosklonov, Jenny Knapp, Frédéric Grenouillet, Yasuhito Sako, Eric Delabrousse, Marie-Pascale Brientini, Carine Richou, Anne Minello, Anca-Teodora Antonino, Michel Gillet, Akira Ito, Georges André Mantion, Dominique Angèle Vuitton.   

Abstract

Liver transplantation (LT) is currently contraindicated in patients with residual or metastatic alveolar echinococcosis (AE) lesions. We evaluated the long-term course of such patients who underwent LT and were subsequently treated with benzimidazoles. Clinical, imaging, serological, and therapeutic data were collected from 5 patients with residual/recurrent AE lesions who survived for more than 15 years. Since 2004, [(18) F]-2-fluoro-2-deoxyglucose (FDG)-positron emission tomography (PET) images were available, and the levels of serum antibodies (Abs) against Echinococcus multilocularis-recombinant antigens were evaluated. Median survival time after LT was 21 years. These patients were from a prospective cohort of 23 patients with AE who underwent LT: 5 of 8 patients with residual/recurrent AE and 4 of 9 patients without residual/recurrent AE were alive in September 2009. High doses of immunosuppressive drugs, the late introduction of therapy with benzimidazoles, its withdrawal due to side effects, and nonadherence to this therapy adversely affected the prognosis. Anti-Em2(plus) and anti-rEm18 Ab levels and standard FDG-PET enabled the efficacy of therapy on the growth of EA lesions to be assessed. However, meaningful variations in Ab levels were observed below diagnostic cutoff values; and in monitoring AE lesions, images of FDG uptake taken 3 hours after its injection were more sensitive than images obtained 1 hour after its injection. In conclusion, benzimidazoles can control residual/recurrent AE lesions after LT. Using anti-rEm18 or anti-Em2(plus) Ab levels and the delayed acquisition of FDG-PET images can improve the functional assessment of disease activity. The potential recurrence of disease, especially in patients with residual or metastatic AE lesions, should not be regarded as a contraindication to LT when AE is considered to be lethal in the short term.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21455928     DOI: 10.1002/lt.22299

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  19 in total

1.  Application of a Three-Dimensional Reconstruction Technique in Liver Autotransplantation for End-Stage Hepatic Alveolar Echinococcosis.

Authors:  Yi-Biao He; Lei Bai; Yi Jiang; Xue-Wen Ji; Qin-Wen Tai; Jin-Ming Zhao; Jin-Hui Zhang; Wen-Ya Liu; Hao Wen
Journal:  J Gastrointest Surg       Date:  2015-05-13       Impact factor: 3.452

2.  Management of Advanced Hepatic Alveolar Echinococcosis: Report of 42 Cases.

Authors:  Bo Qu; Long Guo; Guannan Sheng; Fei Yu; Guannan Chen; Yupeng Wang; Yuan Shi; Hanxiang Zhan; Yi Yang; Xiaoyan Du
Journal:  Am J Trop Med Hyg       Date:  2017-04-06       Impact factor: 2.345

3.  Development of a Real-Time PCR for a Sensitive One-Step Coprodiagnosis Allowing both the Identification of Carnivore Feces and the Detection of Toxocara spp. and Echinococcus multilocularis.

Authors:  Jenny Knapp; Gérald Umhang; Marie-Lazarine Poulle; Laurence Millon
Journal:  Appl Environ Microbiol       Date:  2016-05-02       Impact factor: 4.792

4.  Impact of affected lymph nodes on long-term outcome after surgical therapy of alveolar echinococcosis.

Authors:  Andreas Hillenbrand; Annika Beck; Wolfgang Kratzer; Tilmann Graeter; Thomas F E Barth; Julian Schmidberger; Peter Möller; Doris Henne-Bruns; Beate Gruener
Journal:  Langenbecks Arch Surg       Date:  2018-06-16       Impact factor: 3.445

5.  Clinical outcomes of Ex Vivo liver resection and liver autotransplantation for hepatic alveolar echinococcosis.

Authors:  Hai Wang; Qiaoyu Liu; Zhaoming Wang; Feng Zhang; Xiangcheng Li; Xuehao Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-08-11

Review 6.  Echinococcus metacestode: in search of viability markers.

Authors:  Bruno Gottstein; Junhua Wang; Oleg Blagosklonov; Frédéric Grenouillet; Laurence Millon; Dominique A Vuitton; Norbert Müller
Journal:  Parasite       Date:  2014-11-28       Impact factor: 3.000

7.  Endoscopic Treatment of Biliary Stenosis in Patients with Alveolar Echinococcosis--Report of 7 Consecutive Patients with Serial ERC Approach.

Authors:  Marija Stojkovic; Thomas Junghanss; Mira Veeser; Tim F Weber; Peter Sauer
Journal:  PLoS Negl Trop Dis       Date:  2016-02-24

8.  30-yr course and favorable outcome of alveolar echinococcosis despite multiple metastatic organ involvement in a non-immune suppressed patient.

Authors:  Karine Bardonnet; Dominique A Vuitton; Frédéric Grenouillet; Georges A Mantion; Eric Delabrousse; Oleg Blagosklonov; Jean-Philippe Miguet; Solange Bresson-Hadni
Journal:  Ann Clin Microbiol Antimicrob       Date:  2013-01-02       Impact factor: 3.944

Review 9.  Helminths and immunological tolerance.

Authors:  Chris J C Johnston; Henry J McSorley; Stephen M Anderton; Stephen J Wigmore; Rick M Maizels
Journal:  Transplantation       Date:  2014-01-27       Impact factor: 4.939

10.  Comparison of the serological tests ICT and ELISA for the diagnosis of alveolar echinococcosis in France.

Authors:  Jenny Knapp; Yasuhito Sako; Frédéric Grenouillet; Solange Bresson-Hadni; Carine Richou; Houssein Gbaguidi-Haore; Akira Ito; Laurence Millon
Journal:  Parasite       Date:  2014-07-25       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.